TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04259723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR during TAVI
Description: Virtual Reality (VR) glasses
Study: NCT03487692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes MESSAGES Program
Description: Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.

Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes MESSAGES Program (second trial)
Description: During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
Study: NCT06200142

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics
Description: Untargeted metabolomics in bloodspots and in plasma

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WES and WGS
Description: WES reanalysis and WGS analysis
Study: NCT00830791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941 20 mg
Description: Two 10-mg tablets of MK-0941 administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941 20 mg
Description: Two 10-mg tablets of MK-0941 administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941 20 mg
Description: Two 10-mg tablets of MK-0941 administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941 5 mg
Description: MK-0941 administered as one single 5-mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941 5 mg
Description: MK-0941 administered as one single 5-mg tablet.
Study: NCT02878356

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training
Description: Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training
Description: Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training
Description: Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training + supervision half
Description: Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular MI-training + supervision full
Description: Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
Study: NCT00617669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion given every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion given every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10 mg oral once daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo oral tablet once daily
Study: NCT00297024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
Study: NCT04367571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative treatment (OMT)
Description: OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual Placebo (MP)
Description: The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3).
Study: NCT03938753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audéo M90-T
Description: Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
Study: NCT03121651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RL-adaptive application
Description: Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~1. young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~2. young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~3. young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened.
Study: NCT02697110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Edutainment based intervention
Description: Edutainment intervention package
Study: NCT04013243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
Study: NCT01109056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion 0.05%
Description: One drop in the study eye (or eyes) administered four times daily (QID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop in the study eye (or eyes) administered four times daily (QID)
Study: NCT02052414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin ER
Description: Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits.
Study: NCT00716833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxibe
Description: Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
Study: NCT04397666

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: conjunctival RT PCR
Description: conjunctival sample in covid-19 patients
Study: NCT01670578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Study: NCT02355873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AN69ST hemofilter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN69 hemofilter
Study: NCT02480036

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IORT with Kyphoplasty
Description: IORT with kyphoplasty is give concurrently for the treatment of spinal metastases

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrabeam®
Study: NCT04140760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symprove
Description: A liquid probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symprove placebo product
Description: An inert placebo
Study: NCT01491438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary
Description: PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary
Description: Twice a week (days 1 and 4) during 12 weeks
Study: NCT02527200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Study: NCT04647981

Intervention type: OTHER
Intervention: Xpert® Bladder Cancer Monitor Test
Description: The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
Study: NCT03196700

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
Study: NCT04124497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: * Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg once daily on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22
Study: NCT02744820

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GMC-252-L-Lysine Salt
Description: 1 dose by oral route, once a day, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GMC-252-L-Lysine Salt
Description: 1 dose by oral route, once a day, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GMC-252-L-Lysine Salt
Description: 1 dose by oral route, once a day, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GMC-252-L-Lysine Salt
Description: 1 dose by oral route, once a day, 28 days
Study: NCT01165840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: 100 mg PO x 1 dose
Study: NCT03862651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
Study: NCT02744820

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching doses by oral route, once a day, 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching doses by oral route, once a day, 28 days
Study: NCT02310126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (multi-focal)
Description: Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (multi-focal)
Description: Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
Study: NCT01392430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin
Description: Discontinuation of prophylaxis for opportunistic infections
Study: NCT02646865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Enhanced Cognitive-Behavioral Therapy
Description: 12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: 12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol
Study: NCT04152174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined extracorporeal blood purification
Description: Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRRT
Description: Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)
Study: NCT03660020

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Local anesthetic
Description: ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase
Description: hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
Study: NCT02310126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (sphere)
Description: Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A (sphere)
Description: Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
Study: NCT06403839

Intervention type: PROCEDURE
Intervention: No preoperative dental screening
Description: Discontinuance of mandatory preoperative dental screening prior surgical valve replacement which also can include oral surgery.
Study: NCT01711242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study: NCT02506959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study: NCT01711242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT02506959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00832338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel with Cytoxan
Description: Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
Study: NCT00742105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGT226
Study: NCT01414218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor as a Way of Life Seminar
Description: One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
Study: NCT02693886

Intervention type: OTHER
Intervention: doctor experience

Intervention type: OTHER
Intervention: doctor experience
Study: NCT02058498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
Study: NCT01711242

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT03945279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB100
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB100
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB100
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB100
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB100
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB100
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT02154646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study: NCT02071940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 capsules 1000mg/day as monotherapy
Study: NCT00743964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 50 mg/m2 iv on day 1
Study: NCT03485989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hazelnuts
Description: Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
Study: NCT01737814

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00743964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, capecitabine
Description: Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, capecitabine
Description: Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
Study: NCT01912898

Intervention type: DEVICE
Intervention: No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D
Study: NCT01942863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water exchange single balloon enteroscopy
Description: Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 insufflation single balloon enteroscopy
Description: Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedural Requirements
Description: SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
Study: NCT01737814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MST-188